Non-metastatic castration-resistant prostate cancer, a disease state misnomer that is a seriously unmet therapeutic need
Non-metastatic (M0) castration-resistant prostate cancer (CRPC) is truly a misnomer. It is meant to highlight a prostate cancer disease state that solely exists because of the use of prostate-specific antigen (PSA). In most fields, patients either have localized disease or radiographically-detectable metastatic disease. Since PSA is a highly sensitive measure of detection, our field is able to detect microscopic metastases due to limits of standard imaging modalities.
Evan Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Professor, Department of Medical Oncology, University of Washington School of Medicine
- Member, Fred Hutchinson Cancer Research Center
- Assistant Fellowship Director, Hematology and Oncology Fellowship Training Program, University of Washington and Fred Hutchinson Cancer Research Center.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.